{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:18Z","timestamp":1792813338953,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["4-22-PDFPM-06"],"award-info":[{"award-number":["4-22-PDFPM-06"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304245"],"award-info":[{"award-number":["82304245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02753-1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:54:37Z","timestamp":1746536077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study"],"prefix":"10.1186","volume":"24","author":[{"given":"Weihong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Til","family":"St\u00fcrmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2753_CR1","doi-asserted-by":"crossref","unstructured":"Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, Shaw JE, Paciorek CJ, Singleton RK, Pires AB, Stevens GA. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077\u201393.","DOI":"10.1016\/S0140-6736(24)02317-1"},{"issue":"1","key":"2753_CR2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1186\/s12889-022-13759-9","volume":"22","author":"Y Yan","year":"2022","unstructured":"Yan Y, Wu T, Zhang M, Li C, Liu Q, Li F. Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health. 2022;22(1):1382.","journal-title":"BMC Public Health"},{"issue":"1","key":"2753_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154.","journal-title":"Cardiovasc Diabetol"},{"key":"2753_CR4","doi-asserted-by":"crossref","unstructured":"Quinn L, Haas LB, Burke SD. Cardiovascular disease in the older adult with diabetes. Diabetes management in long-term settings: a clinician\u2019s guide to optimal care for the elderly: American Diabetes Association; 2014.","DOI":"10.2337\/9781580404730.14"},{"key":"2753_CR5","doi-asserted-by":"crossref","unstructured":"Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2).","DOI":"10.3390\/jcdd6020019"},{"issue":"Suppl 1","key":"2753_CR6","first-page":"S179","volume":"47","author":"10","year":"2024","unstructured":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218.","journal-title":"Diabetes Care"},{"issue":"1","key":"2753_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/agm2.12294","volume":"7","author":"L Guo","year":"2024","unstructured":"Guo L, Xiao X. Guideline for the management of diabetes mellitus in the elderly in China (2024 Edition). Aging Med (Milton). 2024;7(1):5\u201351.","journal-title":"Aging Med (Milton)"},{"issue":"6","key":"2753_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/hr.2011.24","volume":"34","author":"R Yang","year":"2011","unstructured":"Yang R, Smolders I, Dupont AG. Blood pressure and renal hemodynamic effects of angiotensin fragments. Hypertens Res. 2011;34(6):674\u201383.","journal-title":"Hypertens Res"},{"issue":"6","key":"2753_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1357-2725(02)00273-X","volume":"35","author":"B Tom","year":"2003","unstructured":"Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin-(1\u20137), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol. 2003;35(6):792\u2013801.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"2753_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","volume":"174","author":"J Cheng","year":"2014","unstructured":"Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773\u201385.","journal-title":"JAMA Intern Med"},{"issue":"15","key":"2753_CR11","doi-asserted-by":"publisher","first-page":"e0256","DOI":"10.1097\/MD.0000000000010256","volume":"97","author":"X Lv","year":"2018","unstructured":"Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis. Med (Baltim). 2018;97(15):e0256.","journal-title":"Med (Baltim)"},{"issue":"15","key":"2753_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"key":"2753_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijcard.2015.07.053","volume":"199","author":"CJ Shih","year":"2015","unstructured":"Shih CJ, Chu H, Ou SM, Chen YT. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study. Int J Cardiol. 2015;199:283\u20139.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2753_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/HJH.0000000000000804","volume":"34","author":"CJ Shih","year":"2016","unstructured":"Shih CJ, Chen HT, Chao PW, Kuo SC, Li SY, Yang CY, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study. J Hypertens. 2016;34(3):567\u201374. discussion 75.","journal-title":"J Hypertens"},{"key":"2753_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12933-016-0365-x","volume":"15","author":"LS Wu","year":"2016","unstructured":"Wu LS, Chang SH, Chang GJ, Liu JR, Chan YH, Lee HF, et al. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Cardiovasc Diabetol. 2016;15:56.","journal-title":"Cardiovasc Diabetol"},{"key":"2753_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijcard.2016.04.096","volume":"215","author":"PY Pai","year":"2016","unstructured":"Pai PY, Muo CH, Sung FC, Ho HC, Lee YT. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes\u2014a real-world population study in Taiwan. Int J Cardiol. 2016;215:114\u20139.","journal-title":"Int J Cardiol"},{"key":"2753_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijcard.2017.08.030","volume":"249","author":"SY Choi","year":"2017","unstructured":"Choi SY, Choi BG, Rha SW, Byun JK, Shim MS, Li H, et al. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. Int J Cardiol. 2017;249:48\u201354.","journal-title":"Int J Cardiol"},{"key":"2753_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2018.08.038","volume":"277","author":"JK Byun","year":"2018","unstructured":"Byun JK, Choi BG, Rha SW, Choi SY, Jeong MH. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Atherosclerosis. 2018;277:130\u20135.","journal-title":"Atherosclerosis"},{"issue":"8","key":"2753_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2753_CR20","doi-asserted-by":"publisher","first-page":"e019698","DOI":"10.1136\/bmjopen-2017-019698","volume":"8","author":"H Lin","year":"2018","unstructured":"Lin H, Tang X, Shen P, Zhang D, Wu J, Zhang J, et al. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese electronic health records research in Yinzhou (CHERRY) study. BMJ Open. 2018;8(2):e019698.","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"2753_CR21","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31\u20134.","journal-title":"Saudi J Anaesth"},{"issue":"7","key":"2753_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2753_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/00003088-198510050-00001","volume":"10","author":"SH Kubo","year":"1985","unstructured":"Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Clin Pharmacokinet. 1985;10(5):377\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"2753_CR24","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/jch.14056","volume":"22","author":"BM Gebresillassie","year":"2020","unstructured":"Gebresillassie BM, Debay YB. Characteristics, treatment, and outcome of patients with hypertensive crisis admitted to university of Gondar specialized hospital, Northwest Ethiopia: a cross-sectional study. J Clin Hypertens (Greenwich). 2020;22(12):2343\u201353.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"2753_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/archinte.1991.00400040032008","volume":"151","author":"P Angeli","year":"1991","unstructured":"Angeli P, Chiesa M, Caregaro L, Merkel C, Sacerdoti D, Rondana M, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med. 1991;151(4):678\u201382.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2753_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jemermed.2015.07.017","volume":"50","author":"A Kaya","year":"2016","unstructured":"Kaya A, Tatlisu MA, Kaplan Kaya T, Yildirimturk O, Gungor B, Karatas B, et al. Sublingual versus oral captopril in hypertensive crisis. J Emerg Med. 2016;50(1):108\u201315.","journal-title":"J Emerg Med"},{"issue":"5","key":"2753_CR27","first-page":"429","volume":"75","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"2753_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al. Comparative first-line effectiveness and safety of ACE (Angiotensin-Converting Enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591\u2013603.","journal-title":"Hypertension"},{"issue":"1","key":"2753_CR29","doi-asserted-by":"publisher","first-page":"e001010","DOI":"10.1136\/openhrt-2019-001010","volume":"6","author":"D Ko","year":"2019","unstructured":"Ko D, Azizi P, Koh M, Chong A, Austin P, Stukel T, et al. Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. Open Heart. 2019;6(1):e001010.","journal-title":"Open Heart"},{"issue":"11","key":"2753_CR30","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2337\/dca24-0012","volume":"47","author":"Y Tian","year":"2024","unstructured":"Tian Y, Qiu Z, Wang F, Deng S, Wang Y, Wang Z, et al. Associations of diabetes and prediabetes with mortality and life expectancy in China: A National study. Diabetes Care. 2024;47(11):1969\u201377.","journal-title":"Diabetes Care"},{"issue":"1","key":"2753_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320.","journal-title":"Clin Kidney J"},{"issue":"5","key":"2753_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology"},{"key":"2753_CR33","volume-title":"Causal inference: what if","author":"MARJ Hernan","year":"2020","unstructured":"Hernan MARJ. Causal inference: what if. Boca Raton: Chapman & Hall\/CRC; 2020."},{"issue":"3","key":"2753_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"key":"2753_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","volume":"9","author":"A Marshall","year":"2009","unstructured":"Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2753_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0962280219870836","volume":"29","author":"J Dong","year":"2020","unstructured":"Dong J, Zhang JL, Zeng S, Li F. Subgroup balancing propensity score. Stat Methods Med Res. 2020;29(3):659\u201376.","journal-title":"Stat Methods Med Res"},{"key":"2753_CR37","unstructured":"Hall P. The bootstrap and Edgeworth expansion. Springer Science & Business Media; 2013."},{"issue":"9287","key":"2753_CR38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"Randomised trial of","year":"2001","unstructured":"Randomised trial of. A perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u201341.","journal-title":"Lancet"},{"issue":"3","key":"2753_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353.","journal-title":"N Engl J Med"},{"issue":"12","key":"2753_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225\u201337.","journal-title":"N Engl J Med"},{"issue":"9644","key":"2753_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174\u201383.","journal-title":"Lancet"},{"issue":"9590","key":"2753_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829\u201340.","journal-title":"Lancet"},{"issue":"10","key":"2753_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr., Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"9","key":"2753_CR44","doi-asserted-by":"publisher","first-page":"e1004465","DOI":"10.1371\/journal.pmed.1004465","volume":"21","author":"PJ Baptiste","year":"2024","unstructured":"Baptiste PJ, Wong AYS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Effectiveness and risk of ARB and ACEi among different ethnic groups in England: a reference trial (ONTARGET) emulation analysis using UK clinical practice research datalink Aurum-linked data. PLoS Med. 2024;21(9):e1004465.","journal-title":"PLoS Med"},{"issue":"10211","key":"2753_CR45","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816\u201326.","journal-title":"Lancet"},{"issue":"1","key":"2753_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/HYPERTENSIONAHA.119.14002","volume":"75","author":"P Oras","year":"2020","unstructured":"Oras P, H\u00e4bel H, Skoglund PH, Svensson P. Elevated blood pressure in the emergency department: a risk factor for incident cardiovascular disease. Hypertension. 2020;75(1):229\u201336.","journal-title":"Hypertension"},{"issue":"13","key":"2753_CR47","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71(13):1474\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"7551","key":"2753_CR48","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","volume":"332","author":"SE McDowell","year":"2006","unstructured":"McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177\u201381.","journal-title":"BMJ"},{"issue":"6","key":"2753_CR49","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/CIRCULATIONAHA.121.057835","volume":"145","author":"FH Messerli","year":"2022","unstructured":"Messerli FH, Bavishi C, Bangalore S. Why are we still prescribing angiotensin-converting enzyme inhibitors?? Circulation. 2022;145(6):413\u20135.","journal-title":"Circulation"},{"key":"2753_CR50","first-page":"14","volume":"13","author":"L Guo","year":"2021","unstructured":"Guo L, Xiao X, Gerontology N, Geriatrics C, Association D. Guideline for the management of diabetes mellitus in the elderly in China (2021 edition). Chin J Diabetes Mellitus. 2021;13:14\u201346.","journal-title":"Chin J Diabetes Mellitus"},{"issue":"1","key":"2753_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/ageing\/afp192","volume":"39","author":"S Kamaruzzaman","year":"2010","unstructured":"Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British women\u2019s heart and health study. Age Ageing. 2010;39(1):51\u20136.","journal-title":"Age Ageing"},{"issue":"10","key":"2753_CR52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/jhh.2014.130","volume":"29","author":"C Di Stefano","year":"2015","unstructured":"Di Stefano C, Milazzo V, Totaro S, Sobrero G, Ravera A, Milan A, et al. Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic. J Hum Hypertens. 2015;29(10):599\u2013603.","journal-title":"J Hum Hypertens"},{"key":"2753_CR53","unstructured":"Chinese guideline for diagnosis and management of cough in primary care. (2024). Chin J Gen Pract. 2024;23(08):793\u2013812."},{"issue":"1","key":"2753_CR54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12906-021-03392-1","volume":"21","author":"SY Hong","year":"2021","unstructured":"Hong SY, Lansky E, Kang SS, Yang M. A review of Pears (Pyrus spp.), ancient functional food for modern times. BMC Complement Med Ther. 2021;21(1):219.","journal-title":"BMC Complement Med Ther"},{"issue":"11","key":"2753_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/jhh.2017.48","volume":"31","author":"DM van der Laan","year":"2017","unstructured":"van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens. 2017;31(11):687\u201394.","journal-title":"J Hum Hypertens"},{"issue":"9","key":"2753_CR56","first-page":"609","volume":"17","author":"S Vegter","year":"2011","unstructured":"Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609\u201316.","journal-title":"Am J Manag Care"},{"issue":"2","key":"2753_CR57","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jval.2013.11.011","volume":"17","author":"MH Alsabbagh","year":"2014","unstructured":"Alsabbagh MH, Lemstra M, Eurich D, Lix LM, Wilson TW, Watson E, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17(2):288\u201396.","journal-title":"Value Health"},{"key":"2753_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jclinepi.2018.06.009","volume":"103","author":"EJ Murray","year":"2018","unstructured":"Murray EJ, Caniglia EC, Swanson SA, Hern\u00e1ndez-D\u00edaz S, Hern\u00e1n MA. Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. J Clin Epidemiol. 2018;103:10\u201321.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2753_CR59","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.119.14360","volume":"75","author":"CG Derington","year":"2020","unstructured":"Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National health and nutrition examination survey 2005\u20132016. Hypertension. 2020;75(4):973\u201381.","journal-title":"Hypertension"},{"issue":"4","key":"2753_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/14737167.2019.1567338","volume":"19","author":"S Malo","year":"2019","unstructured":"Malo S, Rabanaque MJ, Orlando V, Limongelli G, Feja C, Aguilar-Palacio I, et al. Prescribing pattern of antihypertensive drugs in two European cohorts: a population-based database study. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):463\u201371.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2753_CR61","doi-asserted-by":"publisher","first-page":"889047","DOI":"10.3389\/fphar.2022.889047","volume":"13","author":"D Kalini\u0107","year":"2022","unstructured":"Kalini\u0107 D, \u0160krbi\u0107 R, Vuli\u0107 D, Stojakovi\u0107 N, Stoisavljevi\u0107-\u0160atara S, Stojiljkovi\u0107 MP, et al. Trends in antihypertensive medicine utilization in the Republic of Srpska, Bosnia and Herzegovina: an eleven-year follow-up. Front Pharmacol. 2022;13:889047.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2753_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/07853890.2022.2162113","volume":"55","author":"R Yang","year":"2023","unstructured":"Yang R, Tang J, Kuang M, Liu H. Analysis of prescription status of antihypertensive drugs in Chinese patients with hypertension based on real-world study. Ann Med. 2023;55(1):276\u201384.","journal-title":"Ann Med"},{"issue":"8","key":"2753_CR63","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41440-024-01706-7","volume":"47","author":"S Natsume","year":"2024","unstructured":"Natsume S, Satoh M, Murakami T, Sasaki M, Metoki H. The trends of antihypertensive drug prescription based on the Japanese National data throughout the COVID-19 pandemic period. Hypertens Res. 2024;47(8):2086\u201390.","journal-title":"Hypertens Res"},{"key":"2753_CR64","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/CLEP.S265966","volume":"12","author":"M Jung","year":"2020","unstructured":"Jung M, Choo E, Lee S. Comprehensive trends and patterns of antihypertensive prescriptions using a nationwide claims database in Korea. Clin Epidemiol. 2020;12:963\u201375.","journal-title":"Clin Epidemiol"},{"key":"2753_CR65","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/CLEP.S265619","volume":"12","author":"J Davidson","year":"2020","unstructured":"Davidson J, Banerjee A, Muzambi R, Smeeth L, Warren-Gash C. Validity of acute cardiovascular outcome diagnoses recorded in European electronic health records: A systematic review. Clin Epidemiol. 2020;12:1095\u2013111.","journal-title":"Clin Epidemiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02753-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02753-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02753-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:03:49Z","timestamp":1746536629000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02753-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02753-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"Ethics approval and consent to participate","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study used only deidentified data and thus was deemed not to require informedconsent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WZ, TW, NH, PS, HL, XG, YX all have no conflicts of interest that are directly relevant to the content of this article or outside the submitted work. TS receives investigator-initiated research funding and support as Principal Investigator (R01AG056479) from the National Institute on Aging (NIA), and as Co-Investigator (R01CA277756) from the National Cancer Institute, National Institutes of Health (NIH). He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC Clinical and Translational Science Award (UM1TR004406), co-Director of the Human Studies Consultation Core, NC Diabetes Research Center (P30DK124723), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, Boehringer Ingelheim, Astellas, and Sarepta), and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology, University of North Carolina at Chapel Hill. Dr. St\u00fcrmer does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}